Literature DB >> 21950736

Polymorphisms of ADORA2A modulate psychomotor vigilance and the effects of caffeine on neurobehavioural performance and sleep EEG after sleep deprivation.

S Bodenmann1, C Hohoff1, C Freitag1, J Deckert1, J V Rétey1, V Bachmann1, H-P Landolt1.   

Abstract

BACKGROUND AND
PURPOSE: Prolonged wakefulness impairs sustained vigilant attention, measured with the psychomotor vigilance task (PVT), and induces a compensatory increase in sleep intensity in recovery sleep, quantified by slow-wave activity (SWA) in the sleep electroencephalogram (EEG). These effects of sleep deprivation are counteracted by the adenosine receptor antagonist caffeine, implying involvement of the adenosine neuromodulator/receptor system. To examine a role for adenosine A(2A) receptors, we investigated whether variation of the A(2A) receptor gene (ADORA2A) modified effects of caffeine on PVT and SWA after sleep deprivation. EXPERIMENTAL APPROACH: A haplotype analysis of eight single-nucleotide polymorphisms of ADORA2A was performed in 82 volunteers. In 45 young men carrying five different allele combinations, we investigated the effects of prolonged waking and 2 × 200 mg caffeine or 2 × 100 mg modafinil on psychomotor vigilance, sleepiness, and the waking and sleep EEG. KEY
RESULTS: Throughout extended wakefulness, the carriers of haplotype HT4 performed faster on the PVT than carriers of non-HT4 haplotype alleles. In haplotype HT4, caffeine failed to counteract the waking-induced impairment of PVT performance and the rebound of SWA in recovery sleep. However, caffeine was effective in non-HT4 allele carriers, and modafinil reduced the consequences of prolonged waking, independently of ADORA2A haplotype. CONCLUSIONS AND IMPLICATIONS: Common genetic variation of ADORA2A is an important determinant of psychomotor vigilance in rested and sleep-deprived state. It also modulates individual responses to caffeine after sleep deprivation. These findings demonstrate a role for adenosine A(2A) receptors in the effects of prolonged wakefulness on vigilant attention and the sleep EEG.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21950736      PMCID: PMC3372839          DOI: 10.1111/j.1476-5381.2011.01689.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

1.  Adenosinergic mechanisms contribute to individual differences in sleep deprivation-induced changes in neurobehavioral function and brain rhythmic activity.

Authors:  Julia V Rétey; Martin Adam; Julie M Gottselig; Ramin Khatami; Roland Dürr; Peter Achermann; Hans-Peter Landolt
Journal:  J Neurosci       Date:  2006-10-11       Impact factor: 6.167

2.  A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep.

Authors:  J V Rétey; M Adam; R Khatami; U F O Luhmann; H H Jung; W Berger; H-P Landolt
Journal:  Clin Pharmacol Ther       Date:  2007-02-28       Impact factor: 6.875

3.  The neural basis of the psychomotor vigilance task.

Authors:  Sean P A Drummond; Amanda Bischoff-Grethe; David F Dinges; Liat Ayalon; Sara C Mednick; M J Meloy
Journal:  Sleep       Date:  2005-09       Impact factor: 5.849

4.  A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans.

Authors:  J V Rétey; M Adam; E Honegger; R Khatami; U F O Luhmann; H H Jung; W Berger; H-P Landolt
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-12       Impact factor: 11.205

Review 5.  Prostaglandins and adenosine in the regulation of sleep and wakefulness.

Authors:  Zhi-Li Huang; Yoshihiro Urade; Osamu Hayaishi
Journal:  Curr Opin Pharmacol       Date:  2006-11-28       Impact factor: 5.547

Review 6.  Modafinil: a review of neurochemical actions and effects on cognition.

Authors:  Michael J Minzenberg; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2007-08-22       Impact factor: 7.853

Review 7.  Sleep homeostasis: a role for adenosine in humans?

Authors:  Hans-Peter Landolt
Journal:  Biochem Pharmacol       Date:  2008-03-04       Impact factor: 5.858

8.  The effect of caffeine to increase reaction time in the rat during a test of attention is mediated through antagonism of adenosine A2A receptors.

Authors:  Guy A Higgins; Michael E Grzelak; Annamarie J Pond; Mary E Cohen-Williams; Robert A Hodgson; Geoffrey B Varty
Journal:  Behav Brain Res       Date:  2007-07-17       Impact factor: 3.332

9.  Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption.

Authors:  Marilyn C Cornelis; Ahmed El-Sohemy; Hannia Campos
Journal:  Am J Clin Nutr       Date:  2007-07       Impact factor: 7.045

10.  Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety.

Authors:  Emma Childs; Christa Hohoff; Jürgen Deckert; Ke Xu; Judith Badner; Harriet de Wit
Journal:  Neuropsychopharmacology       Date:  2008-02-27       Impact factor: 7.853

View more
  36 in total

1.  "No thanks, coffee keeps me awake": individual caffeine sensitivity depends on ADORA2A genotype.

Authors:  Hans-Peter Landolt
Journal:  Sleep       Date:  2012-07-01       Impact factor: 5.849

2.  Foraging alters resilience/vulnerability to sleep disruption and starvation in Drosophila.

Authors:  Jeffrey Donlea; Averi Leahy; Matthew S Thimgan; Yasuko Suzuki; Bryon N Hughson; Marla B Sokolowski; Paul J Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

3.  2B-Alert Web: An Open-Access Tool for Predicting the Effects of Sleep/Wake Schedules and Caffeine Consumption on Neurobehavioral Performance.

Authors:  Jaques Reifman; Kamal Kumar; Nancy J Wesensten; Nikolaos A Tountas; Thomas J Balkin; Sridhar Ramakrishnan
Journal:  Sleep       Date:  2016-12-01       Impact factor: 5.849

4.  Randomized, double-blind, placebo-controlled, crossover study of the effects of repeated-dose caffeine on neurobehavioral performance during 48 h of total sleep deprivation.

Authors:  Devon A Hansen; Sridhar Ramakrishnan; Brieann C Satterfield; Nancy J Wesensten; Matthew E Layton; Jaques Reifman; Hans P A Van Dongen
Journal:  Psychopharmacology (Berl)       Date:  2018-12-11       Impact factor: 4.530

Review 5.  Caffeine Use Disorder: A Comprehensive Review and Research Agenda.

Authors:  Steven E Meredith; Laura M Juliano; John R Hughes; Roland R Griffiths
Journal:  J Caffeine Res       Date:  2013-09

6.  Dopaminergic role in regulating neurophysiological markers of sleep homeostasis in humans.

Authors:  Sebastian C Holst; Alessia Bersagliere; Valérie Bachmann; Wolfgang Berger; Peter Achermann; Hans-Peter Landolt
Journal:  J Neurosci       Date:  2014-01-08       Impact factor: 6.167

7.  Sustained attention performance during sleep deprivation associates with instability in behavior and physiologic measures at baseline.

Authors:  Eric Chern-Pin Chua; Sing-Chen Yeo; Ivan Tian-Guang Lee; Luuan-Chin Tan; Pauline Lau; Shiwei Cai; Xiaodong Zhang; Kathiravelu Puvanendran; Joshua J Gooley
Journal:  Sleep       Date:  2014-01-01       Impact factor: 5.849

8.  Circadian gene variants influence sleep and the sleep electroencephalogram in humans.

Authors:  Anne-Marie Chang; Andrew C Bjonnes; Daniel Aeschbach; Orfeu M Buxton; Joshua J Gooley; Clare Anderson; Eliza Van Reen; Sean W Cain; Charles A Czeisler; Jeanne F Duffy; Steven W Lockley; Steven A Shea; Frank A J L Scheer; Richa Saxena
Journal:  Chronobiol Int       Date:  2016-04-18       Impact factor: 2.877

9.  Impaired cognitive flexibility during sleep deprivation among carriers of the Brain Derived Neurotrophic Factor (BDNF) Val66Met allele.

Authors:  Leilah K Grant; Sean W Cain; Anne-Marie Chang; Richa Saxena; Charles A Czeisler; Clare Anderson
Journal:  Behav Brain Res       Date:  2017-09-22       Impact factor: 3.332

Review 10.  Neurobehavioral Effects and Biomarkers of Sleep Loss in Healthy Adults.

Authors:  Namni Goel
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09-25       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.